Fraser; Graeme Lovat

Patent Applications and Registrations

Patent applications and USPTO patent grants for Fraser; Graeme Lovat.The latest application filed is for "novel chiral n-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, phar".

Company Profile

6.4.5

Fraser; Graeme Lovat - Bousval BE
Fraser; Graeme Lovat - Sousva[ BE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazi- nes as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof Grant 10,941,151 - Hoveyda , et al. March 9, 2	2021-03-09
Novel Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines As Selective Nk-3 Receptor Antagonists, Phar App 20200283447 - Hoveyda; Hamid R. ; et al.	2020-09-10
Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-A]pyrazi- nes as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof Grant 10,683,295 - Hoveyda , et al.	2020-06-16
Novel Nk-3 Receptor Selective Antagonist Compounds, Pharmaceutical Composition And Methods For Use In Nk-3 Receptors Mediated Di App 20200125564 - Hoveyda; Hamid R. ; et al.	2020-04-23
NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders Grant 10,544,150 - Hoveyda , et al. Ja	2020-01-28
Novel Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines As Selective Nk-3 Receptor Antagonists, Pharmaceutical Composition, Methods For Use In Nk-3 Receptor Mediated Disorders And Chiral Synthesis Thereof App 20190023711 - Hoveyda; Hamid R. ; et al.	2019-01-24
Novel Nk-3 Receptor Selective Antagonist Compounds, Pharmaceutical Composition And Methods For Use In Nk-3 Receptors Mediated Disorders App 20180194772 - Hoveyda; Hamid R. ; et al.	2018-07-12
NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders Grant 8,871,761 - Hoveyda , et al. October 28, 2	2014-10-28
Novel Nk-3 Receptor Selective Antagonist Compounds, Pharmaceutical Composition And Methods For Use In Nk-3 Receptors Mediated Disorders App 20130023530 - Hoveyda; Hamid R. ; et al.	2013-01-24

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.